Parocin; reumoxicam; Movicox; Mobic; Mobicox; Movalis; Meloxicamum; Uticox;
| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Meloxicam (Parocin; Movicox; Meloxicamum; Mobic; Mobicox; reumoxicam; Movalis; Uticox), an approved medication used to treat pain and inflammation in rheumatic arthritis and osteoarthritis, is a potent non-steroidal anti-inflammatory drug (NSAID) which acts as a selective COX inhibitor with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively. I is used to relieve pain and fever effects. Studies suggest that Meloxicam is Cox-2 preferential, therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. It shows potent anti-inflammatory, antipyretic, and analgesic effects with low gastrointestinal toxicity in animal models.
| ln Vitro |
Compound 5, meloxicam, is a non-steroidal anti-inflammatory drug that suppresses COX activity. Its IC50 values for COX-2 and COX-1 are 0.49 µM and 36.6 µM, respectively[1]. At 0.25–25 µg/mL, meloxicam does not exhibit any cytotoxicity on MDCK or CF41.Mg tumor cells, but it suppresses COX+ tumor cells. Additionally, doxorubicin and meloxicam do not work synergistically on CF41.Mg cells. Meloxicam (0.25 µg/mL) inhibits the migration and invasion of CF41.Mg cells, reduces the production of MMP-2, and increases β-catenin phophorylation in CF41.Mg cells; however, it has no effect on apoptosis in CF41.Mg cells[2].
|
||
|---|---|---|---|
| ln Vivo |
In mice, paw liking time is considerably reduced by meloxicam (10 mg/kg) alone or in combination with rutin on the first day by 55% and 49%, respectively, compared to the formalin-treated group; however, the combination does not significantly reduce time on the third day. Additionally, meloxicam alone or in combination with rutin reduces MDA contents, activates liver SOD activities, lowers relative liver weights, inhibits IL-1β content, and considerably lowers the number of positive caspase-3 immunoreactive cells in mice[3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40(6):980-9.
[2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. [3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2) |
| Molecular Formula |
C14H13N3O4S2
|
|
|---|---|---|
| Molecular Weight |
351.4
|
|
| CAS # |
71125-38-7
|
|
| Related CAS # |
Meloxicam-d3;942047-63-4;Meloxicam-d3-1;1227358-55-5;Meloxicam sodium;71125-39-8;Meloxicam-13C,d3;1309936-00-2
|
|
| SMILES |
S1(C2=C([H])C([H])=C([H])C([H])=C2C(=C(C(N([H])C2=NC([H])=C(C([H])([H])[H])S2)=O)N1C([H])([H])[H])O[H])(=O)=O
|
|
| InChi Key |
DWMREKMVXIFPFM-ACCUITESSA-N
|
|
| InChi Code |
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
|
|
| Chemical Name |
(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 1 mg/mL (2.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05702827 | Recruiting | Drug: Bupivacaine-Meloxicam | Stress Urinary Incontinence Surgical Incision |
TriHealth Inc. | January 23, 2023 | Phase 3 |
| NCT01161147 | Completed | Drug: Meloxicam | Healthy | Dr. Reddy's Laboratories Limited | October 2004 | Phase 1 |
| NCT01161134 | Completed | Drug: Meloxicam | Healthy | Dr. Reddy's Laboratories Limited | September 2004 | Phase 1 |
| NCT01801735 | Completed Has Results | Drug: Meloxicam Test Capsules | Osteoarthritis | Iroko Pharmaceuticals, LLC | March 2013 | Phase 3 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
